Optimisation strategies and justification: an example in uterine artery embolisation for fibroids

Radiation risk has to be justified and optimised. This study discusses the radiation risk of uterine artery embolisation (UAE) for the treatment of fibroids. A total of 70 consecutive UAE dosimetry parameters were assessed. Using Monte Carlo simulation, organ and effective doses and dose conversion...

Full description

Saved in:
Bibliographic Details
Published in:Radiation protection dosimetry 2005-01, Vol.117 (1-3), p.50-53
Main Authors: Vetter, S., Schultz, F. W., Strecker, E.-P., Zoetelief, J.
Format: Article
Language:English
Subjects:
Adult
Arteries - pathology
Body Mass Index
Dose-Response Relationship, Radiation
Embolization, Therapeutic - methods
Female
Fluoroscopy - methods
Humans
Leiomyoma - radiotherapy
Middle Aged
Radiometry - methods
Time Factors
Uterine Diseases - radiotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radiation risk has to be justified and optimised. This study discusses the radiation risk of uterine artery embolisation (UAE) for the treatment of fibroids. A total of 70 consecutive UAE dosimetry parameters were assessed. Using Monte Carlo simulation, organ and effective doses and dose conversion coefficients (DCCs) (mSv Gy cm−2) were calculated. During UAE optimisation, avoidance of oblique views and use of last-image-hold (LIH) documentation instead of digital subtraction angiography (DSA) were investigated. Mean dose–area product (DAP) was 37.1 Gy cm2 (median 23.7 Gy cm2) and mean fluoroscopy time was 18.4 min (median 16.6 min). Dose values decreased as the study progressed: mean DAP for patients 1–21, 68.5 Gy cm2; patients 22–43, 35.7 Gy cm2; and patients 44–69, 13.0 Gy cm2. Average DCC for DSA image procedures was 0.572, yielding a mean effective dose of 29.6 mSv (median 17.1 mSv). For LIH-only procedures, an average DCC of 0.813 was estimated [using mean effective dose: 10.6 mSv (median 8.1 mSv)].
ISSN:0144-8420
1742-3406
DOI:10.1093/rpd/nci717